HLX 801

Drug Profile

HLX 801

Alternative Names: HLX-801; SR 16137; SR-16157

Latest Information Update: 06 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SRI International
  • Developer Helix Therapeutics
  • Class Small molecules
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer

Most Recent Events

  • 27 Sep 2016 HLX 801 licensed to Helix Twelve Pharmaceuticals worldwide before September 2016
  • 27 Sep 2016 Phase-II clinical trials in Breast cancer in USA (PO)
  • 01 Dec 2003 Preclinical trials in Breast cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top